Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)
来自多中心、开放标签、II期研究(REFINE)的Navitoclax联合Ruxolitinib治疗未接受过Janus激酶抑制剂治疗的骨髓纤维化患者的初步安全性和有效性
期刊:Hematological Oncology
影响因子:3.9
doi:10.1002/hon.70180
Passamonti, Francesco; Foran, James M; Tandra, Anand; De Stefano, Valerio; Fox, Maria Laura; Mattour, Ahmad; McMullin, Mary Frances; Perkins, Andrew C; Rodriguez-Macías, Gabriela; Sibai, Hassan A; Polepally, Akshanth R; Sun, Yan; Chopra, Avijeet S; Harb, Jason G; Qin, Qin; Potluri, Jalaja; How, Jonathan